Bufexamac is a hydroxamic-acid NSAID withdrawn from many markets over reports of contact dermatitis and allergic reactions after topical use, retained today mainly as a legacy reference compound for historical formulation support. Simson Pharma's Bufexamac reference standard supports remaining regulatory and analytical obligations.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Bufexamac Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.